BCL2 and lymphoma: ABT-199 was as effective as ABT-737 in prolonging survival of immuno-competent mice bearing aggressive progenitor cell lymphomas (derived from bitransgenic myc/bcl-2 mice) without causing thrombocytopenia.144 Furthermore, ABT-199 was identified as a promising therapeutic option for the treatment of t(11;14) MM145 and AML.146 More strikingly, the first clinical trial using a single dose of ABT-199 in three patients with refractory CLL resulted in a rapid tumor lysis within 24 h in 3 of 3 patients.143